Latest News and Press Releases

Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD Novel subcutaneous delivery may offer a more patient-friendly...

Novel nanomedicine radiotracer crosses blood brain barrier in patients with neuroinflammation Tumor macrophage radiotracer achieves 41.6% peak tumor uptake in preclinical studies REDWOOD CITY,...

REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...

Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments Company...

Subcutaneous administration generally safe and well-tolerated across multiple doses>80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total...

REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...

REDWOOD CITY, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow eyes of...

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...

Ashvattha receives additional financing up to $50 million with new lead investor Tribe Capital and existing investors led by Natural CapitalAshvattha’s at-home monthly subcutaneously-administered HDT...